Lysins as a powerful alternative to combat Bacillus anthracis

Nakonieczna, Aleksandra

DOI: https://doi.org/10.1007/s00253-024-13194-3

IF: 5

2024-06-09

Applied Microbiology and Biotechnology

Abstract:This review gathers all, to the best of our current knowledge, known lysins, mainly bacteriophage-derived, that have demonstrated activity against Bacillus anthracis strains. B. anthracis is a spore-forming, toxin-producing bacteria, naturally dwelling in soil. It is best known as a potential biowarfare threat, an etiological agent of anthrax, and a severe zoonotic disease. Anthrax can be treated with antibiotics (ciprofloxacin, penicillin, doxycycline); however, their administration may take up even to 60 days, and different factors can compromise their effectiveness. Bacterial viruses, bacteriophages (phages), are natural enemies of bacteria and use their lytic enzymes, endolysins (lysins), to specifically kill bacterial cells. Harnessing the potential of lysins to combat bacterial infections holds promise for diminishing antibiotic usage and, consequently, addressing the escalating antibiotic resistance in bacteria. In this context, we list the lysins with the activity against B. anthracis , providing a summary of their lytic properties in vitro and the outcomes observed in animal models. Bacillus cereus strain ATCC 4342/RSVF1, a surrogate for B. anthracis , was also included as a target bacteria.

biotechnology & applied microbiology

What problem does this paper attempt to address?

This paper reviews the use of lysins as a promising alternative strategy to combat Bacillus anthracis, the causative agent of anthrax. B. anthracis is a spore-forming bacterium that produces toxins and poses a potential threat in both biological warfare and bioterrorism. Although antibiotics such as ciprofloxacin, penicillin, and doxycycline can be used to treat anthrax, the increasing antibiotic resistance has prompted scientists to seek new approaches to tackle this challenge.

Lysins are enzymes released by bacteriophages (bacterial viruses) that specifically target and disrupt the bacterial cell wall, leading to bacterial death, and bacteria are less likely to develop resistance against them. Researchers have identified multiple lysins targeting B. anthracis, which can be classified into three main categories based on their amino acid sequence similarity and primary enzymatic activity, with most of them belonging to amidase. These lysins have demonstrated activity against B. anthracis and other members of the Bacillus cereus group in in vitro experiments and have also shown promising results in some animal models.

The paper mentioned that although some lysins have been tested in vitro and animal models, research on lysins targeting B. anthracis is relatively limited. Currently known lysins are mainly obtained from bacteriophages, and their activity, host range, and cell wall binding domains (CBDs) are extensively described. The activity of lysins is usually evaluated using methods such as turbidity reduction or spot assays.

In in vitro experiments, many lysins have shown broad-spectrum activity against different members of the Bacillus cereus group, while specific lysins such as PlyG and PlyPH exhibit high specificity towards B. anthracis. In animal models, lysins such as PlyG, PlyPH, PlyB, and LysB4 have demonstrated therapeutic potential, particularly in combating anthrax infections, leading to a significant improvement in survival rates.

In conclusion, this paper aims to summarize and analyze the existing research on lysins targeting B. anthracis, highlighting their potential as alternatives to antibiotics to address the growing problem of antibiotic resistance and providing a foundation for the development of more effective anthrax treatment strategies in the future.